A5067760465- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Economic and Environmental Valuation
- Ocular Diseases and Behçet’s Syndrome
- Ophthalmology and Visual Impairment Studies
Bayer (Switzerland)
2023-2024
Bayer (Germany)
2016-2021
University of Tübingen
2015
The aim of this study was to assess patients’ views and expectations with regard neovascular age-related macular degeneration (nAMD) intravitreal anti-VEGF therapy (IVT). We conducted a multicenter, non-interventional, prospective cohort including nAMD patients treated IVT in Germany. Patients at least one before enrollment aged ≥50 years were included. Three telephone interviews during 12-month observational period. Here, patient’s beliefs/expectations the disease treatment discussed. Only...
Purpose: To determine the reported rates of intraocular inflammation (IOI) in patients treated with intravitreal aflibercept (IVT-AFL) 2 mg routine clinical practice (ie, outside interventional studies), across all indications and within countries (excluding United States), access to either vial presentation or pre-filled syringe (PFS). Patients methods: A search was conducted using Bayer EYLEA ® Global Safety Pharmacovigilance Database for cases IOI IVT-AFL use between October 2012 March...
The PONS study was conceived to analyze the extent of nonpersistence (NP) and nonadherence (NA) in treatment patients with neovascular age-related macular degeneration everyday clinical practice Germany. Further objectives were identify factors that can affect NP NA outcomes under conditions.Nonpersistence (no contact doctor for at least 3 months) or follow-up 6 weeks) as well data analyzed up 24 months retrospectively 12 prospectively 480 23 centers. Patients interviewed possibly affecting...
To evaluate the real-world effectiveness of intravitreal aflibercept injections in Germany patients with neovascular age-related macular degeneration over 24 months.PERSEUS was a prospective, non-interventional cohort study. The primary endpoint mean change visual acuity (VA) from baseline. Secondary endpoints included proportion VA gain or loss ≥ 15 letters and frequency examinations. Patients regular (bimonthly after 3 monthly during year 1 4 2) irregular (any other) treatment were...
To investigate the influence of treatment regularity with intravitreal aflibercept injections (IVT-AFL injections) on visual acuity (VA) outcomes in patients neovascular age-related macular degeneration (nAMD) enrolled PERSEUS trial who received at least 7 IVT-AFL during first year.
Untersuchung der Effektivität und Sicherheit von ivt. Aflibercept (IVT-AFL) in Behandlung neovaskulären altersbedingten Makuladegeneration unter klinischen Routinebedingungen Deutschland.